Plate Nº 94 · recorded November 18, 2026

Neuroscience & MindReported finding

Nose Drops Carrying mRNA Restored Memory in Aged Mice

mRNA nose drops made aged mice score like young ones on memory tests, with 2.4x more new-neuron markers — no plaques cleared, but cognition improved.

By Marcus Bennett4 min read741 words

In brief

  1. Aged mice receiving mRNA nose drops performed like young mice on memory tests
  2. Treated brains showed 2.4 times more cells marked by new-neuron formation
  3. mRNA-driven BDNF expression lasted up to four days from a single dose
  4. The treatment did not reduce amyloid plaque in an Alzheimer's mouse model
  5. Researchers hope human clinical trials can begin within two years
Experimental Nose Drops Restored Fading Memory And Boosted Neuron Growth In Mice
Plate Nº 94Experimental Nose Drops Restored Fading Memory And Boosted Neuron Growth In Mice — PublicDomainPictures / pixabay

A single round of experimental nose drops raised learning and memory in 18-month-old mice back to youthful levels, and the brains of treated animals showed 2.4 times more cells marked by new-neuron formation than controls. The study, published in Advanced Science by a University of Sydney team, packs mRNA — the same technology behind COVID-19 vaccines — into lipid nanoparticles delivered through the nose.

Why the nose instead of a pill or injection?

The core problem in Alzheimer's treatment is the blood-brain barrier: a tightly sealed filter of cells that blocks most substances in the bloodstream, including helpful drugs, from entering brain tissue. Intranasal delivery sidesteps that wall entirely, because the nasal cavity connects directly to the brain.

Earlier work tried nasal sprays carrying brain-boosting proteins, but proteins degrade quickly in nasal mucus, and sprays can only carry small amounts at a time.

This study changes the approach. The researchers supplied instructions, not the drug itself.

How the delivery actually works

The nose drops carried mRNA — a molecule that tells cells which proteins to build, the same mechanism mRNA vaccines used against SARS-CoV-2. In this case, the mRNA instructed cells in the nose to produce brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival and healthy function.

"BDNF is a particularly potent modulator of learning and memory, shown to enhance synaptic density and neurogenesis," the researchers write in their paper. High BDNF levels track with healthy aging; low levels associate with Alzheimer's disease.

Laboratory tests showed a practical payoff: the mRNA-driven BDNF expression remained detectable in cells for up to four days, giving prolonged therapeutic exposure from a single dose.

What changed for the mice?

In aged mice, the results were striking.

  • Treated mice performed significantly better on memory tests than control animals, reaching levels comparable to young mice.
  • Their brains contained 2.4 times as many cells expressing doublecortin (DCX), a protein linked to the formation of new neurons.

"In aged mice, we saw learning and memory significantly increased, returning animal cognition to its youthful prime," says geneticist Greg Neely of the University of Sydney.

A separate experiment used a mouse model of Alzheimer's disease. The BDNF treatment again improved cognitive and memory performance and raised DCX-positive cell counts in the hippocampus, the brain's memory hub. One clear limit: the treatment did not reduce amyloid plaque, the protein clumps that accumulate in Alzheimer's brains.

Why failing to clear plaques may not matter

That apparent failure is the study's most interesting nuance. Several prospective Alzheimer's treatments have done the reverse — cleared amyloid clumps without restoring cognition.

"Our approach seems to work not by clearing plaques but by supporting the health, survival and connectivity of neurons themselves," Neely says. "It raises the possibility these therapies could eventually work alongside each other."

In other words, the treatment may not replace neurons already lost, but it can still improve brain health in a diseased brain. For patients who already have Alzheimer's, that distinction matters enormously — and combining plaque-clearing drugs with neuron-supporting ones could prove complementary.

What stands between mice and patients?

Plenty, by the researchers' own account. The technique has only been demonstrated in mice, and human anatomy differs where it counts.

"Before we can trial this therapy in patients, we need to perform a series of safety studies in animals," Neely says. "It is a very promising pathway but human noses are different from mouse noses, so we will need to test our drugs in humans before we know whether it will work."

The team hopes clinical trials could begin within the next two years, pending those safety studies.

A platform, not just one drug

The mRNA cargo is also swappable. Beyond BDNF, the researchers say the same delivery system could potentially carry instructions for other neurotrophic proteins, such as nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF).

"If we can proceed quickly to clinical trials in humans, this approach could represent a world-first non-invasive delivery system to treat Alzheimer's that bypasses the blood-brain barrier," Neely says.

One caveat deserves repeating: cognition restored in aged mice does not guarantee cognition restored in people. The four-day protein expression, the 2.4-fold neuron-formation signal, and the plaque-neutral results all come from rodents. The human nose will now decide whether the concept travels.

via sciencealert.com (Source)

Filed under

  • alzheimer-s-disease
  • mrna-therapeutics
  • intranasal-delivery
  • bdnf
  • neurogenesis
Share this article:

More from Marcus Bennett

Marcus Bennett

Show full bio

News editor covering regulation, policy and their impact on general science news at SciBeat.

495 articles

Nearby plates

« Previous article